FIELD: chemistry.
SUBSTANCE: invention relates to compounds selected from 1-(4-(2-((2-(4-fluoro-3-(trifluoromethoxy)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(4-(2-((2-(3-bromophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3.5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(4-(2-((2-(4-fluoro-3-(trifluoromethyl)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(4-(2-((2-(3-fluoro-4-(trifluoromethoxy)phenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(4-(2-((2-(2,2-difluorobenzo[c1][1,3]dioxol-5-yl)-4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)-3,5-dimethylphenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(3,5-dimethyl-4-(2-((4-oxo-2-(3-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione; 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-1,3-diazaspiro[4.4]nonane-2,4-dione; 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione; 5-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-2-oxa-5,7-diazaspiro[3.4]octane-6,8-dione and 4-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-4,6-diazaspiro[2.4]heptane-5,7-dione. Invention also relates to pharmaceutical compositions having PTH-like effects for activating the intracellular cAMP response based on said compounds.
EFFECT: obtaining novel compounds and pharmaceutical compositions based thereon, possessing high metabolic stability and strong PTH-like effects that can be used in medicine for the prevention or treatment of osteoporosis or hypoparathyroidism.
11 cl, 6 tbl, 1 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING HYDANTOIN DERIVATIVES | 2014 |
|
RU2701168C2 |
| NEW SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INDOLEAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE INHIBITORS | 2017 |
|
RU2741911C2 |
| STABILISER COMPOSITIONS CONTAINING SUBSTITUTED CHROMAN COMPOUNDS AND METHODS OF USE | 2013 |
|
RU2662823C2 |
| PROCESS ADDITIVES AND THEIR USE IN ROTARY MOLDING | 2011 |
|
RU2742578C2 |
| PROCESS ADDITIVES AND USE THEREOF IN ROTARY MOULDING | 2011 |
|
RU2597918C2 |
| NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2814288C1 |
| STABILIZED POLYOLEFIN OBTAINED BY ROTATIONAL MOULDING | 2019 |
|
RU2831778C2 |
| IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, POSSESSING ANTIPROLIFERATIVE ACTIVITY | 2010 |
|
RU2555999C2 |
| COMPOSITION STABILIZED AGAINST OXIDATIVE, THERMAL, AND PHOTOINITIATED DESTRUCTION AND A METHOD FOR STABILIZING POLYAMIDE, POLYESTER, AND POLYACETAL | 1998 |
|
RU2210578C2 |
| POLYETHYLENE PIPE | 2018 |
|
RU2817113C2 |
